NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN
OR INTO THE UNITED STATES, CANADA, AUSTRALIA, HONG KONG OR JAPAN OR SUCH
OTHER JURISDICTIONS WHERE THE OFFERING AND SALE OF THE NEW SHARES AND
THE SUBSCRIPTION RIGHTS IS RESTRICTED BY LAW.
The Financial Supervisory Authority of Norway has approved the following
prospectus:
Prospectus for rights offering and subsequent listing of 100,000,000 new
shares (the "New Shares") each with a par value of NOK 0.20 at a
subscription price of NOK 0.50 per New Share (the "Prospectus")
DiaGenic ASA
The information contained in the Prospectus relates to a rights offering
(the "Rights Offering") and subsequent listing of 100,000,000 New Shares
each with a par value of NOK 0.20 at a subscription price of NOK 0.50
per New Share (the "Subscription Price"), with subscription rights
("Subscription Rights") for existing shareholders (the "Existing
Shareholders") of DiaGenic ASA (the "Company") as of the end of 25
February 2014 as appearing in the Norwegian Central Securities
Depository ("VPS") on 28 February 2014 (the "Record Date"). The Rights
Offering is fully underwritten by an underwriting syndicate.
Each Eligible Shareholder will be granted 12.25509 Subscription Rights
for each Share registered as held by such Eligible Shareholder as of the
Record Date rounded down to the nearest whole Subscription Right. Each
Subscription Right will, subject to applicable securities laws, give the
right to subscribe for and be allocated one New Share.
Subscription Period for the Rights Offering:
The subscription period for the Rights Issue commences on 17 March 2014
and expires at 17:30 hours, Central European Time ("CET"), on 31 March
2014 (the "Subscription Period"). The Subscription Rights will be
tradable on Oslo Børs during the Subscription Period under the ticker
symbol "DIAG S".
Important notice: Subscription Rights that are not used to subscribe for
New Shares before the end of the Subscription Period will have no value
and will lapse without compensation to the holder.
Manager for the Rights Issue is Arctic Securities ASA
The information in this notice is not complete. For further information
see Prospectus dated 14 March 2014 which is available online at
www.diagenic.com and www.arcticsec.no. The Prospectus can also be
obtained physically from the Manager and will be available to the public
from 17 March 2014:
The Manager:
Arctic Securities ASA
P.O. Box 1833 Vika
Haakon VII's gt. 5
0123 Oslo
Norway
www.arcticsec.no